journal
MENU ▼
Read by QxMD icon Read
search

Journal of Child and Adolescent Psychopharmacology

journal
https://www.readbyqxmd.com/read/28799787/increased-risk-of-diabetes-among-6-24-year-olds-using-second-generation-antipsychotics
#1
Shan Xing, Todd A Lee
OBJECTIVES: The goal of this study was to estimate the association between use of second generation antipsychotics (SGAs) and type 2 diabetes (T2DM) among commercially insured children and young adults 6-24 years compared to users of non-SGA psychotropic medications. METHODS: Using the Truven MarketScan Commercial Claims and Encounters Database, new users of SGA and non-SGA psychotropic medications (anxiolytics, antidepressants, hypnotics, and mood stabilizers) between July 1, 2009 and December 31, 2013 who were 6-24 years of age and had continuous coverage ≥180 days before their index date (i...
August 11, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28783382/development-of-metabolic-syndrome-in-drug-naive-adolescents-after-12-months-of-second-generation-antipsychotic-treatment
#2
Christina Power Sjo, Anne Dorte Stenstrøm, Anders Bo Bojesen, Jacob Stampe Frølich, Niels Bilenberg
OBJECTIVES: Mental illness is often accompanied by poor physical health and shorter life expectancy. Second-generation antipsychotics (SGAs) are suspected of increasing cardiovascular risk, possibly through development of metabolic syndrome (MetS), and the risk of adverse outcome is even higher if obesity or metabolic aberration starts in childhood or adolescence. METHODS: Drug-naive adolescents were recruited after contact with an outpatient Psychosis Team. Changes relative to baseline in body mass index (BMI), waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), triglycerides (TG), and high-density lipoprotein (HDL) cholesterol were determined through regular follow-ups...
August 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28771386/predictors-of-long-term-risky-driving-behavior-in-the-multimodal-treatment-study-of-children-with-attention-deficit-hyperactivity-disorder
#3
Jessica A Johnson, Ewgeni Jakubovski, Margot O Reed, Michael H Bloch
OBJECTIVE: This study examines predictors of later risky driving behavior in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Stepwise logistic regression and receiver operating characteristic (ROC) analysis were used to explore baseline predictors of risky driving behavior for adolescents who completed the 8-year follow-up assessment in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA). RESULTS: Stepwise logistic regression analysis explained 19% of the total variance in risky driving behavior...
August 3, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28771381/psychometric-properties-and-factor-structures-of-the-korean-version-of-children-s-depression-rating-scale-revised
#4
Kyoung-Min Kim, Sojeong Nam, Jae-Won Choi, A-Hyun Jung, Soon-Beom Hong, Jun Won Kim, Soo Yeon Kim, Eunji Kim, Jae-Won Kim
OBJECTIVE: The Children's Depression Rating Scale-Revised (CDRS-R) is a valid instrument for the assessment of depressive symptoms in youth, but this measure is yet to be validated in Korea. Thus, the present study aimed to evaluate the validity of the Korean version of the CDRS-R and to determine its factor structures. METHODS: This study included 66 youths between 12 and 17 years of age who participated as part of an ongoing study investigating biomarkers of the antidepressant response and suicidal events in depressed youth...
August 3, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28759262/a-double-blind-and-placebo-controlled-trial-of-aripiprazole-in-symptomatic-youths-at-genetic-high-risk-for-bipolar-disorder
#5
Robert L Findling, Eric A Youngstrom, Brieana M Rowles, Elizabeth Deyling, Jacqui Lingler, Robert J Stansbrey, Molly McVoy, Sarah Lytle, Joseph R Calabrese, Nora K McNamara
OBJECTIVE: To determine if acute treatment with aripiprazole (APZ) would be superior to treatment with placebo in reducing dysfunctional symptoms of elevated mood and/or irritability in symptomatic children and adolescents at familial high risk for bipolar disorder (BPD) whose mood episodes occur spontaneously. These are patients we have previously referred to as suffering from "cyclotaxia." METHODS: This was single-site, randomized, double-blind, placebo-controlled outpatient clinical trial in which youths aged 5-17 years who met diagnostic criteria for either cyclothymic disorder (CYC) or BPD not otherwise specified (BP-NOS) were randomly assigned to receive either APZ or placebo...
July 31, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28731778/a-pharmacologic-algorithm-for-youth-who-are-at-high-risk-for-bipolar-disorder
#6
Christopher D Schneck, Kiki D Chang, Manpreet K Singh, Melissa P DelBello, David J Miklowitz
OBJECTIVE: Depression and brief periods of manic symptoms are linked to a significant risk of progression to bipolar disorder (BD) in children who have a first-degree relative with BD I or II. However, little evidence exists to guide the pharmacologic management of children with these high-risk phenotypes. We propose a pharmacological treatment algorithm for high-risk youth and present results on its use in a study of children with a first-degree relative with BD. METHODS: Subjects were 40 youth (mean 12...
July 21, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28723227/extended-release-guanfacine-does-not-show-a-large-effect-on-tic-severity-in-children-with-chronic-tic-disorders
#7
Tanya K Murphy, Thomas V Fernandez, Barbara J Coffey, Omar Rahman, Allison Gavaletz, Camille E Hanks, Caitlin S Tillberg, Laura Ibanez Gomez, Denis G Sukhodolsky, Lily Katsovich, Lawrence Scahill
OBJECTIVE: To evaluate the tolerability, safety, and preliminary efficacy of extended-release guanfacine in children with chronic tic disorders, including Tourette's disorder (collectively referred to as CTD). METHODS: This was a multisite, 8-week, randomized, double-blind, placebo-controlled trial. The primary outcome measure was the Yale Global Tic Severity Scale (YGTSS) total score. Key secondary outcomes included the Improvement item of Clinical Global Impressions-Improvement (CGI-I) scale and the Tic Symptom Self-report (TSSR)...
July 19, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28722481/clinical-management-of-pediatric-acute-onset-neuropsychiatric-syndrome-part-i-psychiatric-and-behavioral-interventions
#8
Margo Thienemann, Tanya Murphy, James Leckman, Richard Shaw, Kyle Williams, Cynthia Kapphahn, Jennifer Frankovich, Daniel Geller, Gail Bernstein, Kiki Chang, Josephine Elia, Susan Swedo
OBJECTIVE: This article outlines the consensus guidelines for symptomatic treatment for children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Syndrome Associated with Streptococcal Infection (PANDAS). METHODS: Extant literature on behavioral, psychotherapeutic, and psychopharmacologic treatments for PANS and PANDAS was reviewed. Members of the PANS Research Consortium pooled their clinical experiences to find agreement on treatment of PANS and PANDAS symptoms...
July 19, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28722464/overview-of-treatment-of-pediatric-acute-onset-neuropsychiatric-syndrome
#9
Susan E Swedo, Jennifer Frankovich, Tanya K Murphy
No abstract text is available yet for this article.
July 19, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28719227/simvastatin-as-an-adjunctive-therapy-to-risperidone-in-treatment-of-autism-a-randomized-double-blind-placebo-controlled-clinical-trial
#10
Ehsan Moazen-Zadeh, Fatemeh Shirzad, Mohammad-Ali Karkhaneh-Yousefi, Rasoul Khezri, Mohammad-Reza Mohammadi, Shahin Akhondzadeh
OBJECTIVES: Providing novel treatments for autism has been a subject of long-standing research. Based on etiopathological findings, we aim at assessing potential therapeutic effects of statins, here simvastatin, on autism symptoms for the first time. METHODS: In this randomized, double-blind, placebo-controlled, parallel-group 10-week clinical trial, 70 drug-free children aged 4 to 12 years old with diagnosis of autistic disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, who had an Aberrant Behavior Checklist-Community (ABC-C) scale irritability subscale score of ≥12, were equally randomized to receive either simvastatin (20-40 mg/day) or placebo as an adjunct to risperidone (1-2 mg/day) whereas administration of both drugs was started simultaneously from baseline...
July 18, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28714753/pediatric-acute-onset-neuropsychiatric-syndrome-response-to-oral-corticosteroid-bursts-an-observational-study-of-patients-in-an-academic-community-based-pans-clinic
#11
Kayla Brown, Cristan Farmer, Bahare Farhadian, Joseph Hernandez, Margo Thienemann, Jennifer Frankovich
BACKGROUND: Sudden-onset severe obsessive-compulsive symptoms and/or severely restrictive food intake with at least two coinciding, similarly debilitating neuropsychiatric symptoms define Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). When associated with Group A Streptococcus, the syndrome is labeled Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). An abnormal immune response to infection and subsequent neuroinflammation is postulated to play an etiologic role...
July 17, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28708433/physical-health-outcomes-in-preschoolers-with-prior-authorization-for-antipsychotics
#12
Yu-Jung Wei, Xinyue Liu, Nikhil Rao, Marie McPherson, Mary Beth Jones, Regina Bussing, Almut G Winterstein
OBJECTIVE: To examine incidence of adverse health outcomes and associated factors among preschoolers (under age 6) who received antipsychotic treatment through the Florida Medicaid Prior Authorization (PA) program. METHODS: Using Florida's PA registry linked to the state's Medicaid claims data, we ascertained incident outcomes during PA-approved antipsychotic use between April 2008 and September 2015 (7.5 years). Six outcomes associated with use of antipsychotics included: diabetes, obesity, hyperlipidemia, hyperprolactinemia, cardiovascular disease (CVD) (including hypertension, ventricular arrhythmia, and other CVDs), and extrapyramidal symptoms (EPS) (including dystonia, akathisia, parkinsonism, and tardive dyskinesia)...
July 14, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28704066/using-a-multidisciplinary-algorithm-to-treat-self-injurious-behavior-in-a-young-boy-with-developmental-delays
#13
Andrea Courtemanche, Maura Wendland, T Sunny Fenikile, Kathryn Ellerbeck
No abstract text is available yet for this article.
July 13, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28696786/effect-of-early-and-prophylactic-nonsteroidal-anti-inflammatory-drugs-on-flare-duration-in-pediatric-acute-onset-neuropsychiatric-syndrome-an-observational-study-of-patients-followed-by-an-academic-community-based-pediatric-acute-onset-neuropsychiatric-syndrome
#14
Kayla D Brown, Cristan Farmer, G Mark Freeman, Ellen J Spartz, Bahare Farhadian, Margo Thienemann, Jennifer Frankovich
INTRODUCTION: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is characterized by the sudden onset of severe obsessive-compulsive symptoms and/or eating restriction along with at least two coinciding neuropsychiatric symptoms. When associated with group A Streptococcus, the syndrome is labeled Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). An abnormal immune response to infection and subsequent neuroinflammation is postulated to play an etiologic role...
July 11, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28696783/course-of-neuropsychiatric-symptoms-after-introduction-and-removal-of-nonsteroidal-anti-inflammatory-drugs-a-pediatric-observational-study
#15
Ellen J Spartz, G Mark Freeman, Kayla Brown, Bahare Farhadian, Margo Thienemann, Jennifer Frankovich
OBJECTIVE: Accumulating evidence suggests that anti-inflammatory interventions can modulate neuropsychiatric symptoms. Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is characterized by an abrupt and dramatic onset of obsessive-compulsive (OC) symptoms and/or severely restrictive food intake and at least two coinciding, equally debilitating neuropsychiatric symptoms. When associated with group A Streptococcus, the syndrome is labeled Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS)...
July 11, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28686474/randomized-double-blind-placebo-controlled-trial-demonstrates-the-efficacy-and-safety-of-oral-aripiprazole-for-the-treatment-of-tourette-s-disorder-in-children-and-adolescents
#16
Floyd Sallee, Eva Kohegyi, Joan Zhao, Robert McQuade, Kevin Cox, Raymond Sanchez, Alet van Beek, Margaretta Nyilas, William Carson, Roger Kurlan
OBJECTIVES: Aripiprazole modulates dopaminergic and serotonergic pathways that may play a role in the pathogenesis of Tourette's disorder (TD). This trial evaluated the efficacy and safety of oral aripiprazole in the suppression of tics in children and adolescents with TD. METHODS: This phase 3, randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov , NCT01727700) recruited patients who were 7-17 years old with a diagnosis of TD from hospitals, private practices, and research clinics at 76 sites in the United States, Canada, Hungary, and Italy...
July 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28686059/household-diversion-of-prescription-stimulants-medication-misuse-by-parents-of-children-with-attention-deficit-hyperactivity-disorder
#17
Tammy Pham, Ruth Milanaik, Alyson Kaplan, Helen Papaioannou, Andrew Adesman
OBJECTIVES: The primary objective of this study is to investigate household diversion of stimulant medication. Secondary objectives are to examine clinical/demographic predictors of diversion, types of formulations diverted, exposure to household diversion in the media, and storage of prescription stimulants within households. METHODS: Questionnaires were completed by 180 parents of youth who were currently taking stimulant medication for treatment of attention-deficit/hyperactivity disorder (ADHD)...
July 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28665688/epistaxis-as-an-unexpected-side-effect-of-aripiprazole-and-risperidone-treatment-in-two-children-with-two-different-psychiatric-diagnosis
#18
Nagihan Cevher Binici, Sevay Alşen Güney
No abstract text is available yet for this article.
June 30, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28661708/pilot-data-supporting-omega-3-fatty-acids-supplementation-in-medicated-children-with-attention-deficit-hyperactivity-disorder-and-deficits-in-emotional-self-regulation
#19
Timothy E Wilens, Nicholas W Carrellas, Courtney Zulauf, Amy M Yule, Mai Uchida, Andrea Spencer, Joseph Biederman
No abstract text is available yet for this article.
June 29, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28618239/extent-and-risks-of-antipsychotic-off-label-use-in-children-and-adolescents-in-germany-between-2004-and-2011
#20
Carsten Schröder, Michael Dörks, Bianca Kollhorst, Tilo Blenk, Ralf W Dittmann, Edeltraut Garbe, Oliver Riedel
OBJECTIVE: Only little is known about antipsychotic (AP) off-label use (OLU) in pediatric populations. It was the aim of this study to examine the frequency as well as the risks of off-label AP use in underaged patients. METHODS: To calculate the frequency of off-label AP prescriptions for the years 2004-2011, we used claims data of more than two million minors aged 0-17 years. Off-label prescriptions were analyzed with regard to type of OLU, physician specialty, and underlying diagnoses...
June 15, 2017: Journal of Child and Adolescent Psychopharmacology
journal
journal
20144
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"